Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.72B P/E 34.65 EPS this Y -18.40% Ern Qtrly Grth -95.40%
Income 1.32M Forward P/E 82.97 EPS next Y 18.90% 50D Avg Chg -1.00%
Sales 607.52M PEG 10.57 EPS past 5Y -17.31% 200D Avg Chg -11.00%
Dividend N/A Price/Book 1.88 EPS next 5Y 1.69% 52W High Chg -25.00%
Recommedations 2.00 Quick Ratio 1.38 Shares Outstanding 54.74M 52W Low Chg 8.00%
Insider Own 5.12% ROA 0.56% Shares Float 47.71M Beta 0.99
Inst Own 108.02% ROE 0.15% Shares Shorted/Prior 4.68M/4.92M Price 31.53
Gross Margin 86.21% Profit Margin 0.22% Avg. Volume 460,327 Target Price 40.50
Oper. Margin 11.56% Earnings Date May 8 Volume 352,136 Change -0.50%
About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Supernus Pharmaceuticals, Inc. News
04/24/24 Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
04/08/24 Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
04/08/24 Supernus Provides Regulatory Update for SPN-830
03/06/24 Supernus to Participate in Two Upcoming Investor Conferences
03/04/24 11 Best Small Cap Pharma Stocks to Invest In
02/29/24 Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
02/28/24 Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
02/28/24 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
02/28/24 Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
07:30 PM Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
06:50 PM Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
05:00 PM Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
04:05 PM Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
02/26/24 Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
02/20/24 Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
02/13/24 Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
02/05/24 Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
01/14/24 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
12/19/23 Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
12/14/23 Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
SUPN Chatroom

User Image Stock_Titan Posted - 2 days ago

$SUPN Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 https://www.stocktitan.net/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2024-financial-qt6wdkhsycwy.html

User Image StockInvest_us Posted - 3 days ago

Signal alert: $SUPN - Oversold Trend Short (Undervalued) https://stockinvest.us/l/7lrMEZBH7p

User Image Tom1985IT Posted - 1 week ago

$SUPN still amazed why a company this size can’t put their hands on promising CNS asset. it’s been a while since sustainable shareholder value has been generated.

User Image Aigner_Andreas Posted - 1 week ago

TF SELL $SUPN at 29.43 : 29.98 SmallCap 98% Shp 0.67 S 3.18 N 1.03 RSI 36.22% SRSI 0% ADXR 22.29 #stocks #trading #finance #market

User Image gemini112 Posted - 2 weeks ago

$SUPN When is the next catalyst for this stock? I had strange feelings as I saw insiders continue to sell.

User Image Doubledareyou Posted - 2 weeks ago

$SUPN leadership at Supernus may need a shake up. Management lacking vision to bring this once 3billion market cap company to the next level. Current market cap is about 1/2 from its ATH. Complete leadership team has another failure on its hands with this current CRL. Is Supernus just a branded generic product company? IMO.

User Image G101SPM Posted - 2 weeks ago

$SUPN $31.06 ... SELL/TAKE PROFIT on compromised SPM tag. DAC (dollar average cost) $29.05 (2.23.24).

User Image GetVector Posted - 2 weeks ago

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $PERI, $SUPN.

User Image OpenOutcrier Posted - 2 weeks ago

$SUPN (-7.5% pre) Supernus Pharma (SUPN) Provides Regulatory Update for SPN-830, FDA Issues CRL - SI https://ooc.bz/l/29726

User Image DonCorleone77 Posted - 2 weeks ago

$SUPN Supernus: FDA says SPN-830 NDA 'not ready for approval' in present form Supernus Pharmaceuticals announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson's disease under U.S. Food and Drug Administration review. The FDA has issued a Complete Response Letter in response to the Company's New Drug Application for SPN-830. The CRL indicates that the review cycle for the application is complete, but that the application is not ready for approval in its present form. The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA. The first area relates to product quality. The Company recently submitted additional product quality data to the FDA which it has not yet reviewed. The second relates to the master file for the infusion device which is proprietary to the device manufacturer....

User Image ringo2112 Posted - 2 weeks ago

$SUPN ouch.

User Image Stock_Titan Posted - 2 weeks ago

$SUPN Supernus Provides Regulatory Update for SPN-830 https://www.stocktitan.net/news/SUPN/supernus-provides-regulatory-update-for-spn-s77j95ns8mhu.html

User Image marti837 Posted - 2 weeks ago

$SUPN no news

User Image Turd_No_fart Posted - 2 weeks ago

$SUPN hold my beer

User Image Turd_No_fart Posted - 3 weeks ago

$SUPN news yet!

User Image ringo2112 Posted - 3 weeks ago

$SUPN D day and no comments?

User Image princejoel Posted - 3 weeks ago

@SeekinAlohaMills $SUPN coming into that key level, we would see how this reacts to this level, I'd still hold my thesis until the stock proves otherwise.

User Image Doozio Posted - 3 weeks ago

Base is proper n papa huckleberry about to be fresh. Then $supn special happens in 🧠⏰

User Image Blink182rulez Posted - 3 weeks ago

$SUPN

User Image ringo2112 Posted - 03/31/24

$SUPN (this was reason for CRL???)... FDA mentioned at the time that approval of the NDA required inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL did not request additional efficacy and safety clinical studies. Supernus will continue to work closely with the FDA as it reviews the SPN-830 NDA.

User Image Blink182rulez Posted - 1 month ago

$SUPN

User Image marti837 Posted - 1 month ago

$SUPN squeeze

User Image insiderbuyingselling Posted - 1 month ago

$SUPN new insider selling: 14491 shares. http://insiderbuyingselling.com/?t=SUPN

User Image princejoel Posted - 1 month ago

$SUPN: $35.50 and up, I will be looking to open a position with $1-$1.60 stop Depending on the market conditions, generally speaking things have stalled out for a bunch of names and sectors. The market conditions on my mind

User Image insiderbuyingselling Posted - 1 month ago

$SUPN new insider selling: 400 shares. http://insiderbuyingselling.com/?t=SUPN

User Image ringo2112 Posted - 1 month ago

$SUPN so a CRL was issued 5/29/23 and re-submission to FDA 11/2/23 has there been any updates as to correcting the issues of the CRL? I would assume that there would be seeing the re-submission and acceptance of has taken place?...

User Image Blink182rulez Posted - 1 month ago

$SUPN what do we got here some sort of medical device?

User Image StockInvest_us Posted - 1 month ago

Signal alert: $SUPN - Overbought Trend Short (Overvalued) https://stockinvest.us/l/7KzHUpVj5r

User Image marti837 Posted - 1 month ago

$SUPN buy

User Image Golden_Cross Posted - 1 month ago

$SUPN Bullish 50/200-day MA Crossover..

Analyst Ratings
Piper Sandler Overweight Feb 28, 24
Piper Sandler Overweight Nov 9, 23
Piper Sandler Overweight Oct 25, 23
Piper Sandler Overweight May 10, 23
Piper Sandler Overweight Jan 23, 23
Piper Sandler Overweight Aug 31, 22
Jefferies Buy Apr 13, 21
Piper Sandler Overweight Jun 16, 20
Stifel Hold Apr 16, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Jan 10 Sell 27.91 8,000 223,280 85,664 01/12/24
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Jan 10 Option 9.24 8,000 73,920 93,664 01/12/24
Hudson Frederick M. Director Director Nov 15 Sell 28.5 9,093 259,150 33,231 11/17/23
Hudson Frederick M. Director Director Nov 15 Option 9.24 7,457 68,903 42,324 11/17/23
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 30 Sell 32 8,100 259,200 85,249 09/01/23
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 30 Option 23.99 8,100 194,319 93,349 09/01/23
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 25 Sell 31.59 5,135 162,215 85,249 08/29/23
Khattar Jack A. President, CEO President, CEO Feb 02 Sell 42.04 13,732 577,293 804,272 02/06/23
Khattar Jack A. President, CEO President, CEO Feb 02 Option 9.56 22,845 218,398 804,472 02/06/23
Khattar Jack A. President, CEO President, CEO Jan 18 Sell 40.4 4,936 199,414 794,317 01/20/23
Khattar Jack A. President, CEO President, CEO Jan 18 Option 9.56 8,080 77,245 799,253 01/20/23
Hudson Frederick M. Director Director Jan 10 Option 7.90 8,722 68,904 30,985 01/12/23
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Jan 06 Sell 39.9 174 6,943 1,644 01/09/23
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Jan 06 Option 9.13 174 1,589 1,818 01/09/23
NEWHALL CHARLES W III Director Director Dec 28 Option 7.90 8,722 68,904 110,453 12/30/22
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Dec 01 Option 9.13 5,000 45,650 6,644 12/02/22
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Dec 01 Sell 37.48 5,000 187,400 1,644 12/02/22
Khattar Jack A. President, CEO President, CEO Nov 22 Option 9.56 959 9,168 782,018 11/23/22
Khattar Jack A. President, CEO President, CEO Nov 22 Sell 35 600 21,000 781,418 11/23/22
Khattar Jack A. President, CEO President, CEO Nov 21 Option 9.56 848 8,107 781,590 11/22/22
Khattar Jack A. President, CEO President, CEO Nov 21 Sell 35.01 531 18,590 781,059 11/22/22
Khattar Jack A. President, CEO President, CEO Nov 15 Option 9.56 1,783 17,045 781,857 11/17/22
Khattar Jack A. President, CEO President, CEO Nov 15 Sell 35 1,115 39,025 780,742 11/17/22
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Nov 09 Sell 34.97 700 24,479 1,644 11/14/22
Bhatt Padmanabh P. Sr. VP of IP, CSO Sr. VP of IP, CSO Nov 09 Option 9.24 700 6,468 2,344 11/14/22
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 22 Option 7.9 5,000 39,500 92,220 08/23/22
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 22 Sell 35.98 5,000 179,900 87,220 08/23/22
Khattar Jack A. President, CEO President, CEO Aug 16 Option 17.01 48,712 828,591 790,249 08/18/22
Khattar Jack A. President, CEO President, CEO Aug 16 Sell 34.01 14,690 499,607 775,559 08/18/22
Khattar Jack A. President, CEO President, CEO Aug 10 Option 0 44,900 769,878 08/11/22
Khattar Jack A. President, CEO President, CEO Aug 10 Sell 31.22 28,437 887,803 741,441 08/11/22
Khattar Jack A. President, CEO President, CEO Aug 09 Option 0 63,100 764,409 08/10/22
Khattar Jack A. President, CEO President, CEO Aug 09 Sell 31.15 39,431 1,228,276 724,978 08/10/22
Khattar Jack A. President, CEO President, CEO Aug 08 Option 0 192,000 819,216 08/09/22
Khattar Jack A. President, CEO President, CEO Aug 08 Sell 31.76 117,907 3,744,726 701,309 08/09/22
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 04 Sell 32.98 5,000 164,900 87,220 08/05/22
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Aug 04 Option 7.9 5,000 39,500 92,220 08/05/22
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Apr 14 Option 12.98 6,250 81,125 89,451 04/14/21
Martin Tami Tillotson Sr. V.P., Regulatory.. Sr. V.P., Regulatory Affairs Apr 14 Sell 30.98 6,250 193,625 86,326 04/14/21
Schwabe Stefan K.F. Executive Vice Presi.. Executive Vice President & CMO Dec 22 Option 12.98 46,347 601,584 49,119 12/22/20
Schwabe Stefan K.F. Executive Vice Presi.. Executive Vice President & CMO Dec 22 Sell 22.1 46,347 1,024,269 2,772 12/22/20
Schwabe Stefan K.F. Executive Vice Presi.. Executive Vice President & CMO Dec 15 Option 11.06 53,653 593,402 56,425 12/15/20
Schwabe Stefan K.F. Executive Vice Presi.. Executive Vice President & CMO Dec 15 Sell 21.93 53,653 1,176,610 2,772 12/15/20
PATRICK GREGORY S Sr. VP Chief Financi.. Sr. VP Chief Financial Officer Nov 10 Option 12.98 5,000 64,900 49,463 11/10/20
PATRICK GREGORY S Sr. VP Chief Financi.. Sr. VP Chief Financial Officer Nov 10 Sell 25 5,000 125,000 44,463 11/10/20
PATRICK GREGORY S Sr. VP, CFO Sr. VP, CFO Nov 06 Option 12.98 5,000 64,900 49,463 11/06/20
PATRICK GREGORY S Sr. VP, CFO Sr. VP, CFO Nov 06 Sell 23 5,000 115,000 44,463 11/06/20
PATRICK GREGORY S Sr. VP, CFO Sr. VP, CFO Oct 15 Option 12.98 15,000 194,700 59,463 10/15/20
PATRICK GREGORY S Sr. VP, CFO Sr. VP, CFO Oct 15 Sell 20.03 15,000 300,450 44,463 10/15/20